ClinicalTrials.gg
RecruitingNCT06187870Updated Jan 10, 2024

Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies

An observational study in Urologic Diseases, Urologic Cancer and Infertility, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-10.

Primary conditionUrologic NeoplasmsRegistry: Urologic DiseasesReclassifiedWhy we changed it
Registry
Urologic Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urologic Neoplasms
Why
  1. The study's listed conditions name Urologic Neoplasms, a narrower term within Urologic Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started Oct 2010; still recruiting 16 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Urologic Neoplasms with a site in Italy — 3 open to participants now, 5 under way, 1 of them phase 3. Urologic Neoplasms · Italy.

Started
2010
the only one that year
Observational
2 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
IRCCS San Raffaele

Among the 14 studies in Urologic Neoplasms with a site in Italy, this one is the only one that started in 2010, is one of 2 observational ones, and was the 13th registered.

Urologic Neoplasms

157 studies on the registry are indexed under Urologic Neoplasms; 42 are open to participants now.

Browse Urologic Neoplasms studies →

Open to participants now

3 of the 14 studies in Urologic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urologic Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The project aims to collect fresh biological material derived both from surgical resections performed in diseases, neoplastic and otherwise, of urological relevance at the level of the prostate, bladder, kidney, testicle and genitourinary organs, and from peripheral blood or other fluids biological samples such as urine, seminal fluid, buccal mucosa, feces or saliva, when available.

Read the detailed description

Significant studies have shown the great potential of research based on access to biobanks which has made it possible to conduct studies and obtain important results through retrospective studies carried out on samples collected some time ago. Thanks to the possibility of accessing human biological samples collected and stored in biological banks, great results have been achieved in the medical field. The project aims to collect fresh biological material deriving from surgical resections performed in neoplastic and non-neoplastic pathologies of urological relevance at the level of the prostate, bladder, kidney, testicle and genitourinary organs, both from biological samples of peripheral blood or other fluids such as urine, seminal fluid, buccal mucosa, feces or saliva, when available.

The possibility of obtaining biological samples from the patient at the time of the first visit or the first biopsy and, subsequently, in conjunction with a possible surgical intervention, could ideally give the possibility of studying the disease from its possible onset to the possible intervention, evaluating the evolution and possible association with circulating diagnostic and prognostic markers. The establishment of this collection of research material will allow access to samples of extreme value for the pathophysiological study of the disease, its origin, mechanisms and markers of progression. The data obtained can also be correlated with the patient's clinical history in order to build an overall vision potentially useful in the design of new therapeutic strategies.

03

Conditions studied

  • Urologic Diseases
  • Urologic Cancer
  • Infertility

Browse trials for

04

In context

Urologic Neoplasms Reclassified

157 studies on the registry are indexed under Urologic Neoplasms; 42 are open to participants now.

This study's planned enrollment of 15,000 is above the median of 174 across 33 observational studies indexed under Urologic Neoplasms.

Browse Urologic Neoplasms studies →

Lead sponsor

IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.

Compared within Urologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urologic Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

People with urological or uro-oncological diseases and infertility

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with an age > 18
  • Ability to read and sign the
  • patients affected by urological or uro-oncological diseases

Exclusion criteria

Exclusion Criteria:

  • People with an age \< 18
  • Incapacity to read and sign the
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15,000 participants (estimated)
Patient registry
No

Interventions

  • OtherCollection of biological data

    Biological samples will be collected from the patient at the time of their access to the Hospital

07

What researchers measure

Primary outcomes

  1. Biological sample

    A biobank is a facility aimed at the collection, management, preservation and distribution of biomaterials and related data for research purposes

    Time frame: Baseline

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2010 (actual). Primary completion is estimated for Oct 2030, 239 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Jan 3, 2024
StartActual
Oct 7, 2010
Primary completionEst.
Oct 6, 2030
CompletionEst.
Oct 6, 2030
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06187870
Lead sponsor
IRCCS San Raffaele
Responsible party
Andrea Salonia (Prof, IRCCS San Raffaele) — Principal investigator
First posted
Jan 3, 2024
Start date
Oct 7, 2010
Primary completion
Oct 6, 2030 (estimated)
Completion
Oct 6, 2030 (estimated)
Last update
Jan 10, 2024

Study contacts

Anna Maria Ferrara
Contact
ferrara.annamaria@hsr.it
0226437795

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion